FY2018 EPS Estimates for Bristol-Myers Squibb Co Decreased by Analyst (BMY)

Bristol-Myers Squibb Co (NYSE:BMY) – Investment analysts at Jefferies Group decreased their FY2018 earnings per share (EPS) estimates for shares of Bristol-Myers Squibb in a report issued on Tuesday. Jefferies Group analyst J. Holford now expects that the biopharmaceutical company will post earnings per share of $3.12 for the year, down from their previous forecast of $3.19. Jefferies Group has a “Hold” rating and a $72.00 price objective on the stock. Jefferies Group also issued estimates for Bristol-Myers Squibb’s FY2019 earnings at $3.76 EPS, FY2020 earnings at $4.30 EPS and FY2022 earnings at $5.69 EPS.

Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $0.75 EPS for the quarter, missing the consensus estimate of $0.77 by ($0.02). Bristol-Myers Squibb had a return on equity of 32.41% and a net margin of 20.56%. The company had revenue of $5.25 billion for the quarter, compared to analyst estimates of $5.20 billion. During the same period last year, the company posted $0.77 EPS. The business’s revenue for the quarter was up 6.7% on a year-over-year basis.

BMY has been the subject of several other research reports. Vetr lowered shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating and set a $63.67 price objective for the company. in a research report on Thursday, September 28th. Piper Jaffray Companies reissued a “hold” rating and issued a $60.00 price objective on shares of Bristol-Myers Squibb in a research report on Friday, October 27th. Cowen reissued a “hold” rating and issued a $65.00 price objective on shares of Bristol-Myers Squibb in a research report on Tuesday, September 19th. Citigroup increased their price objective on shares of Bristol-Myers Squibb to $72.00 and gave the stock a “buy” rating in a research report on Wednesday, October 18th. Finally, Credit Suisse Group reissued a “hold” rating and issued a $61.00 price objective (up previously from $58.00) on shares of Bristol-Myers Squibb in a research report on Friday, October 27th. Three research analysts have rated the stock with a sell rating, eight have given a hold rating and ten have assigned a buy rating to the company’s stock. Bristol-Myers Squibb currently has a consensus rating of “Hold” and a consensus price target of $65.11.

Shares of Bristol-Myers Squibb (BMY) traded up $1.93 during mid-day trading on Wednesday, reaching $61.85. 10,608,137 shares of the company traded hands, compared to its average volume of 7,136,200. Bristol-Myers Squibb has a 1 year low of $46.01 and a 1 year high of $66.10. The company has a quick ratio of 1.46, a current ratio of 1.59 and a debt-to-equity ratio of 0.47. The firm has a market capitalization of $101,230.00, a price-to-earnings ratio of 24.35, a price-to-earnings-growth ratio of 2.30 and a beta of 1.18.

Hedge funds and other institutional investors have recently bought and sold shares of the business. Massey Quick Simon & CO. LLC boosted its stake in Bristol-Myers Squibb by 523.5% during the 3rd quarter. Massey Quick Simon & CO. LLC now owns 1,777 shares of the biopharmaceutical company’s stock valued at $113,000 after acquiring an additional 1,492 shares during the last quarter. Horan Capital Advisors LLC. bought a new position in Bristol-Myers Squibb during the 3rd quarter valued at $122,000. Tradewinds Capital Management LLC raised its holdings in shares of Bristol-Myers Squibb by 34.6% during the second quarter. Tradewinds Capital Management LLC now owns 1,945 shares of the biopharmaceutical company’s stock worth $108,000 after purchasing an additional 500 shares during the period. Atlantic Trust LLC acquired a new stake in shares of Bristol-Myers Squibb during the second quarter worth $111,000. Finally, AllSquare Wealth Management LLC acquired a new stake in shares of Bristol-Myers Squibb during the third quarter worth $134,000. Hedge funds and other institutional investors own 69.74% of the company’s stock.

In other news, EVP Thomas J. Jr. Lynch sold 5,300 shares of the company’s stock in a transaction on Tuesday, December 12th. The shares were sold at an average price of $63.24, for a total value of $335,172.00. Following the completion of the transaction, the executive vice president now directly owns 9,251 shares in the company, valued at $585,033.24. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Theodore R. Samuels II bought 4,000 shares of the firm’s stock in a transaction dated Friday, December 15th. The stock was purchased at an average price of $62.30 per share, with a total value of $249,200.00. Following the completion of the purchase, the director now directly owns 22,000 shares of the company’s stock, valued at approximately $1,370,600. The disclosure for this purchase can be found here. 0.23% of the stock is currently owned by corporate insiders.

The company also recently announced a quarterly dividend, which will be paid on Thursday, February 1st. Stockholders of record on Friday, January 5th will be paid a $0.40 dividend. The ex-dividend date of this dividend is Thursday, January 4th. This is an increase from Bristol-Myers Squibb’s previous quarterly dividend of $0.39. This represents a $1.60 annualized dividend and a dividend yield of 2.59%. Bristol-Myers Squibb’s dividend payout ratio is 62.99%.

TRADEMARK VIOLATION NOTICE: “FY2018 EPS Estimates for Bristol-Myers Squibb Co Decreased by Analyst (BMY)” was reported by Week Herald and is the sole property of of Week Herald. If you are accessing this piece on another publication, it was illegally copied and reposted in violation of US & international trademark and copyright legislation. The legal version of this piece can be read at https://weekherald.com/2018/01/17/fy2018-eps-estimates-for-bristol-myers-squibb-co-decreased-by-analyst-bmy.html.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Earnings History and Estimates for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply